Appropriate Castration with Luteinising Hormone Releasing Hormone (LHRH) Agonists: What is the Optimal Level of Testosterone?
- 31 July 2005
- journal article
- Published by Elsevier in European Urology Supplements
- Vol. 4 (5) , 14-19
- https://doi.org/10.1016/j.eursup.2005.04.004
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Role of Luteinising Hormone Releasing Hormone (LHRH) Agonists and Hormonal Treatment in the Management of Prostate CancerEuropean Urology Supplements, 2005
- Rapid polyelectrolyte-based immunofiltration technique for testosterone detection in serum samplesThe Analyst, 2003
- Effective testosterone suppression for patients with prostate cancer: is there a best castration?Urology, 2003
- Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate CancerJournal of Urology, 2002
- Reassessment of the definition of castrate levels of testosterone: implications for clinical decision makingUrology, 2000
- The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancerUrology, 1994
- Effect of Orchidectomy on Serum Concentrations of Testosterone and Dihydrotestosterone in Patients with Prostatic CancerScandinavian Journal of Urology and Nephrology, 1992
- Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic CarcinomaBritish Journal of Urology, 1991
- Leuprolide versus Diethylstilbestrol for Metastatic Prostate CancerNew England Journal of Medicine, 1984
- Reconsideration of Orchiectomy in the Treatment of Advanced Prostatic CarcinomaSouthern Medical Journal, 1977